European Companies Search Engine
EU funding (€2,612,061): LIgand Generator and portable drug discovery platform AT Exascale Hor1 Jan 2021 EU Research and Innovation programme "Horizon"
Overview
Text
LIgand Generator and portable drug discovery platform AT Exascale
Today digital revolution is having a dramatic impact on the pharmaceutical industry and the entire healthcare system. The implementation of machine learning, extreme scale computer simulations, and big data analytics in the drug design and development process offer an excellent opportunity to lower the risk of investment and reduce the time to patient. In LIGATE, we aim to integrate and co-design best in class European open-source components together with proprietary (European) IPs (whose development has already been co-funded by previous H2020 projects) to keep worldwide leadership on Computer-Aided Drug Design (CADD) solutions exploiting today high-end supercomputer and tomorrow Exascale resources, fostering the European competitiveness in this field. The proposed LIGATE solution, in a fully integrated workflow, enables to deliver the result of a drug design campaign with the highest speed along with the highest accuracy; further implementing the auto-tuning the parameters of the solutions to meet the time and resource constraints. This predictability, together with the fully automation of the solution and the availability of the Exascale system, will let run the full in silico drug discovery campaign in less than one day to respond promptly for example to worldwide pandemic crisis. Since the evolution of HPC architectures is heading toward specialization and extreme heterogeneity, including future Exascale architectures, the LIGATE solution focuses also on code portability with the possibility to deploy the CADD platform on any available type of architecture in order not to have a legacy in the hardware. The project plans to make the platform available and open to support the discovery a novel treatment to fight virus infections and multidrug-resistant bacteria. The project will also make available to the research community the outcome of a final simulation.
Funded Companies:
| Company name | Funding amount |
| Chelonia SA | €156,625 |
| Cineca Consorzio Interuniversitario | €248,438 |
| Dompe Farmaceutici S.p.A. | €366,625 |
| E 4 Computer Engineering S.p.A. | €173,742 |
| Kungliga Tekniska Hoegskolan | €194,375 |
| PH3 GmbH | €61,484 |
| Politecnico Di Milano | €358,125 |
| Tofmotion GmbH | €75,147 |
| Universita Degli Studi Di Salerno | €231,875 |
| Universitaet Innsbruck | €303,750 |
| Universitat Basel | €199,750 |
| VSB - Technical University OF Ostrava | €242,125 |
Source: https://cordis.europa.eu/project/id/956137
The filing refers to a past date, and does not necessarily reflect the current state.
